Dolutegravir alone maintains HIV suppression in those treated early

Dolutegravir-based single-drug therapy was an effective long-term maintenance regimen in people who had started treatment soon after acquiring HIV in a small study published in the journal Clinical Infectious Diseases. Participants on dolutegravir alone experienced no treatment failure while their immunological and virological features remained stable throughout the four-year follow-up. These findings from the extended Early Simplified trial suggest the possibility of dolutegravir-based single-drug therapy for a select group of people with HIV, but there are caveats.

Read the full story at Aidsmap.